Q-omics provides the consensus-scored GNRH1 profile across patient tissues and cancer cell-line models. GNRH1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GNRH1 is differentially expressed in 7, with the highest sampling consensus in KIRC. Additionally, GNRH1 RNA expression shows 17,021 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, and UVM as cancer lineages where GNRH1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GNRH1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GNRH1 survival associations across molecular data types. GNRH1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GNRH1 RNA expression–survival associations across cancer types. High GNRH1 expression shows unfavorable associations in KIRC, LIHC, LGG and KICH, but favorable associations in SKCM and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GNRH1 RNA expression.
This table summarizes GNRH1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GNRH1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GNRH1 shows lower tumor expression in BRCA, LUAD and UCEC and higher tumor expression in KIRC, LIHC and CHOL. The KIRC box plot shows higher GNRH1 RNA expression in tumor versus normal tissue (log2 FC = +0.819, t-test p < 0.001).
This table shows molecular features associated with GNRH1 in patient tissues and cancer cell lines. In patient samples, GNRH1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, GNRH1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Myeloma and BLOOD_Leukemia.
